Table 3. Serum levels of TFPI2 and CA125 in the training and validation sets.
| Biomarker | Groups in training set (n) | |||||||
| EMS (n = 71) | non-EMS (n = 43) | BD (n = 8) | Total CCC (n = 29) | Early CCC (n = 18) | Late CCC (n = 11) | non-CCC EOCs (n = 79) | Ut Diseases (TFPI2, n = 38; CA125, n = 32) | |
| TFPI2 (pg/mL) | 137.7 (104.0–191.0) | 132.3 (86.2–186.7) | 151.3 (137.7–192.1) | 781.8 (381.4–1410) | 484.8 (226.3–1044) | 1142 (716.0–1796) | 208.5 (137.7–307.3) | 162.2 (115.3–231.8) |
| CA125 (U/mL) | 45.0 (24–83) | 18.1 (11–31) | 36.0 (24.3–67.75) | 102 (45.5–309.5) | 74.0 (28.8–151.75) | 181.0 (102.0–465.0) | 301 (109–1059) | 16 (9–30.75) |
| Biomarker | Groups in validation set (n) | |||||||
| EMS (n = 17) | non-EMS (n = 23) | BD (n = 15) | Total CCC (n = 7) | Early CCC (n = 4) | Late CCC (n = 3) | non-CCC EOCs (n = 31) | Ut Diseases (TFPI2, n = 58; CA125, n = 42) | |
| TFPI2 (pg/mL) | 182.1 (151.1–213.0) | 151.1 (88.9–182.1) | 151.1 (120.1–213.0) | 518.3 (182.1–934.7) | 335.1 (135.6–690.4) | 934.7 (518.3–2197) | 213.0 (151.1–305.4) | 182.1 (120.1–243.9) |
| CA125 (U/mL) | 58 (36.5–90.5) | 17 (11–25) | 43 (25–80) | 352 (100–1143) | 621.5 (37.0–3472) | 352.0 (123.0–518.0) | 95 (51–419) | 18.5 (11.25–36) |
All tested values are expressed as the median (interquartile range). Abbreviations: EMS, endometriosis; BD, borderline ovarian tumor.